The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]

This article refers to:

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies

Donohue JF, Ozol-Godfrey A, Goodin T, Sanjar S. Int J Chron Obstruct Pulmon Dis. 2020;15:745–754.

The authors have advised there is an error in Figure 4 on page 751. The Q2 subgroup of the placebo arm has the label of “−0.012” which should read “0.012”.

The correct Figure 4 is shown below. The authors apologize for this error.

Figure 4 Pooled analysis of change from baseline in trough FEV₁ at 12 weeks by baseline rescue medication use subgroup (ITT population).

Notes: *p<0.05, **p<0.01, ***p<0.001 versus placebo; n-values represent the number of patients with on-treatment data at week 12.
Abbreviations: BID, twice daily; FEV₁, forced expiratory volume in 1 second; GLY, nebulized glycopyrrolate; ITT, intent-to-treat; LS, least squares; Q, quarter; SE, standard error.